Clinical Trial Update: Phase I/II Trial of a Long Peptide Vaccine (LPV7) Plus TLR Agonists [Phase 1, Phase 2]

View source ↗

Summary

Phase I/II trial evaluating LPV7 vaccine with TLR agonists in melanoma showed completed status with posted results.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Mucosal Melanoma

Drugs mentioned

• LPV7 vaccine (Long Peptide Vaccine (LPV7))
• TLR agonists (TLR agonists)

Snippet

Sponsor: Craig L Slingluff, Jr | Conditions: Melanoma, Metastatic Melanoma | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2023-11-03